ArticlePloS one2012
Evolution of Burkholderia pseudomallei in recurrent melioidosis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 114 citations in OpenAlex.
- Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim-Sulfamethoxazole Resistance in Burkholderia thailandensis.ACS infectious diseases · 2026Article
- Shotgun metagenome sequencing and informatics can accurately form a metagenome-assembled genome (MAG) of the bacterial tier 1 select agentMicrobiology spectrum · 2026Article
- Article
- Comparative genomic analysis of paired clinical isolates from a patient with recurrent melioidosis reveals a low within-host mutation rate.Journal of medical microbiology · 2025Article
- Review
- Case Report: Genetic evolution ofWellcome open research · 2025Article
- Foodborne Infections andVaccines · 2024Review
- Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024Review
- The Rapid Emergence of HypervirulentTropical medicine and infectious disease · 2024Review
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Antibiotic susceptibility of clinicalAntimicrobial agents and chemotherapy · 2023Article
- Phenotypic and genetic alterations ofFrontiers in microbiology · 2023Article
- Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel.Microbiology spectrum · 2022Article
- Highly specific and sensitive detection of Burkholderia pseudomallei genomic DNA by CRISPR-Cas12a.PLoS neglected tropical diseases · 2022Article
- Co-evolutionary Signals Identify Burkholderia pseudomallei Survival Strategies in a Hostile Environment.Molecular biology and evolution · 2022Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Antimicrobial Susceptibility of Western Hemisphere Isolates ofMicrobial drug resistance (Larchmont, N.Y.) · 2021Article
- Common Adaptive Strategies Underlie Within-Host Evolution of Bacterial Pathogens.Molecular biology and evolution · 2021Article
- Burkholderia ubonensis High-Level Tetracycline Resistance Is Due to Efflux Pump Synergy Involving a Novel TetA(64) Resistance Determinant.Antimicrobial agents and chemotherapy · 2021Article
- Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.PLoS neglected tropical diseases · 2021Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 3 countries.
Funding
Abstract
Burkholderia pseudomallei, the etiologic agent of human melioidosis, is capable of causing severe acute infection with overwhelming septicemia leading to death. A high rate of recurrent disease occurs in adult patients, most often due to recrudescence of the initial infecting strain. Pathogen persistence and evolution during such relapsing infections are not well understood. Bacterial cells present in the primary inoculum and in late infections may differ greatly, as has been observed in chronic disease, or they may be genetically similar. To test these alternative models, we conducted whole-genome comparisons of clonal primary and relapse B. pseudomallei isolates recovered six months to six years apart from four adult Thai patients. We found differences within each of the four pairs, and some, including a 330 Kb deletion, affected substantial portions of the genome. Many of the changes were associated with increased antibiotic resistance. We also found evidence of positive selection for deleterious mutations in a TetR family transcriptional regulator from a set of 107 additional B. pseudomallei strains. As part of the study, we sequenced to base-pair accuracy the genome of B. pseudomallei strain 1026b, the model used for genetic studies of B. pseudomallei pathogenesis and antibiotic resistance. Our findings provide new insights into pathogen evolution during long-term infections and have important implications for the development of intervention strategies to combat recurrent melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.